RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma.

Identification and validation of biomarkers with potential clinical utility [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Tissue

Estimated Enrollment:

200

Study Start Date:

August 2010

Estimated Primary Completion Date:

January 2100 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

To comprehensively detect genomic, epigenomic, and transcriptomic aberrations in tissue samples from patients with osteosarcoma that may play a role in chemoresistance and metastasis using high-resolution genome-wide technologies.

To identify recurrent genetic mutations involved in the pathogenesis of osteosarcoma, especially for the development of chemoresistance and metastatic tumors.

To identify and validate these biomarkers for new therapeutic targets for patients with osteosarcoma, especially those with metastatic disease and whose tumors are resistant to standard chemotherapy.

Fresh-frozen samples collected at the time of diagnosis with matched blood DNA (preferred) from patients enrolled on the following osteosarcoma biology protocols:

COG-P9851

COG-AOST06B1

Available clinical outcome data

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

Not specified

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01190943